Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

State of Comparative Effectiveness Research: Benchmark Survey

This article was originally published in RPM Report

Executive Summary

Comparative Effectiveness Research is a phrase with talisman qualities inside the Beltway -- ascribed with almost magical properties to improve product/treatment choices and drive down health care expenditures. Outside the political sphere, the meaning of the term and concepts about how to effect CER are less clear.

You may also be interested in...



Comparative Effectiveness: Knowledge Not Coverage

The health industry's trade association supports a more formal and expanded federal comparative effectiveness research effort, with one caveat: the effort must be devoted to collecting and disseminating informaiton and not be tied directly to coverae or payment decisions. That aligns the health plans with Senate Finance Committee Chairman Max Baucus and creates a potent base for getting comparative effectiveness into upcoming health reform efforts.

Comparative Effectiveness: The Next Gatekeeper to Commercial Success

The hot new buzzword with policymakers is comparative clinical effectiveness, and everyone has an idea on how to make it work. But major questions remain: what might a national effort look like? And will payors use it to restrict access to new drugs?

Comparative Effectiveness Research and the Environment for Health Care Decision-Making

During the last five years, there has beenenormous changes in the health care environment: the implementation of the Affordable Care Act and its many provisions, including the creation of PCORI; the development of health exchanges and a move toward value-based payments, most notably in Medicare programs. In the midst of all this change, what impact will comparative effectiveness research have on health care decision-making?

Topics

UsernamePublicRestriction

Register

PS080839

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel